# REPRIEVE: pitavastatine vermindert CV-events bij HIV — NEJM

*geplaatst 2023-08-24 · Cholesterol · The New England journal of medicine · doi 10.1056/NEJMoa2304146 · https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/*

De REPRIEVE-trial in de NEJM toonde dat pitavastatine cardiovasculaire events met 35% verminderde bij HIV-patiënten met laag tot matig CV-risico. De trial werd voortijdig gestaakt wegens duidelijk voordeel. Statines zijn nu bewezen effectief voor primaire preventie bij HIV.

## English: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

The REPRIEVE trial demonstrated that pitavastatin reduced major cardiovascular events by 35% in people living with HIV who had low-to-moderate cardiovascular risk. The trial was stopped early for efficacy, providing the first definitive evidence for statin therapy in primary cardiovascular prevention among HIV-infected individuals.

## Abstract (original, from the publication)

BACKGROUND: The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in this population are needed. METHODS: In this phase 3 trial, we randomly assigned 7769 participants with HIV infection with a low-to-moderate risk of cardiovascular disease who were receiving antiretroviral therapy to receive daily pitavastatin calcium (at a dose of 4 mg) or placebo. The primary outcome was the occurrence of a major adverse cardiovascular event, which was defined as a composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral arterial ischemia, revascularization, or death from an undetermined cause. RESULTS: The median age of the participants was 50 years (interquartile range, 45 to 55); the median CD4 count was 621 cells per cubic millimeter (interquartile range, 448 to 827), and the HIV RNA value was below quantification in 5250 of 5997 participants (87.5%) with available data. The trial was stopped early for efficacy after a median follow-up of 5.1 years (interquartile range, 4.3 to 5.9). The incidence of a major adverse cardiovascular event was 4.81 per 1000 person-years in the pitavastatin group and 7.32 per 1000 person-years in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], 0.48 to 0.90; P = 0.002). Muscle-related symptoms occurred in 91 participants (2.3%) in the pitavastatin group and in 53 (1.4%) in the placebo group; diabetes mellitus occurred in 206 participants (5.3%) and in 155 (4.0%), respectively. CONCLUSIONS: Participants with HIV infection who received pitavastatin had a lower risk of a major adverse cardiovascular event than those who received placebo over a median follow-up of 5.1 years. (Funded by the National Institutes of Health and others; REPRIEVE ClinicalTrials.gov number, NCT02344290.).

Auteurs: Steven K Grinspoon, Kathleen V Fitch, Markella V Zanni, Carl J Fichtenbaum, Triin Umbleja, Judith A Aberg, Edgar T Overton, Carlos D Malvestutto, Gerald S Bloomfield, Judith S Currier, Esteban Martinez, Jhoanna C Roa, Marissa R Diggs, Evelynne S Fulda, Kayla Paradis, Stephen D Wiviott, Borek Foldyna, Sara E Looby, Patrice Desvigne-Nickens, Beverly Alston-Smith, Jorge Leon-Cruz, Sara McCallum, Udo Hoffmann, Michael T Lu, Heather J Ribaudo, Pamela S Douglas

---
Bron: The New England journal of medicine, https://doi.org/10.1056/NEJMoa2304146. Bijgewerkt 2026-07-03T13:29:36Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.